Top

BMC Infectious Diseases

Published in:

Open Access 01-12-2022 | Bronchoscopy | Case report

Invasive Aspergillus outbreak in inhalation injury: a case presentation and literature review

Authors: Shengli Liu, Zonghang Li, Jiansheng Zheng, Ning He

Published in: BMC Infectious Diseases | Issue 1/2022

Abstract

Background

Invasive pulmonary aspergillosis often occurs in patients with poor immune function, who abuse steroids or broad-spectrum antibiotics, or who use intravenous drugs. Among the Aspergillus genus of pulmonary infection, Aspergillus fumigatus is the most important pathogen, followed by Aspergillus flavus, Aspergillus niger, and Aspergillus terreus. Inhalation injury complicated by Aspergillus infection has atypical clinical manifestations. Diagnosis is difficult, and it is easy to make mistakes in treatment. Moreover, there are few cases of burn inhalation injury complicated with pulmonary Aspergillus.

Case presentation

We report a case of severe burns combined with severe inhalation injury, early pulmonary aspergillosis, and severe respiratory failure due to treatment discontinuation. Through analyzing the processes of diagnosis and treatment in the present case and performing a literature review, we explore feasible diagnosis and treatment plans.

Conclusions

Early application of a variety of diagnostic measures can be used to identify Aspergillus infection, and targeted anti-infection treatment is likely to reverse a severe adverse prognosis.

Corcione S, Lupia T, Raviolo S, Montrucchio G, Trentalange A, Curtoni A, et al. Putative invasive pulmonary aspergillosis within medical wards and intensive care units: a 4-year retrospective, observational, single-centre study. Intern Emerg Med. 2021. https://doi.org/10.1007/s11739-021-02705-z.CrossRefPubMedPubMedCentral

Taccone FS, Van den Abeele AM, Bulpa P, Misset B, Meersseman W, Cardoso T, et al. Epidemiology of invasive aspergillosis in critically ill patients: clinical presentation, underlying conditions, and outcomes. Crit Care. 2015;19(1):7. https://doi.org/10.1186/s13054-014-0722-7.CrossRefPubMedPubMedCentral

Chang C, Gershwin ME. The myth of mycotoxins and mold injury. Clin Rev Allergy Immunol. 2019;57(3):449–55. https://doi.org/10.1007/s12016-019-08767-4.CrossRefPubMed

Desoubeaux G, Bailly É, Chandenier J. Diagnosis of invasive pulmonary aspergillosis: updates and recommendations. Med Mal Infect. 2014;44(3):89–101. https://doi.org/10.1016/j.medmal.2013.11.006.CrossRefPubMed

Lamoth F, Calandra T. Early diagnosis of invasive mould infections and disease. J Antimicrob Chemother. 2017;72(Suppl_1):i19–28. https://doi.org/10.1093/jac/dkx030.CrossRefPubMed

Nucci M, Carlesse F, Cappellano P, Varon AG, Seber A, Garnica M, et al. Earlier diagnosis of invasive fusariosis with Aspergillus serum galactomannan testing. PLoS ONE. 2014;9(1): e87784. https://doi.org/10.1371/journal.pone.0087784.CrossRefPubMedPubMedCentral

Shah AA, Hazen KC. Diagnostic accuracy of histopathologic and cytopathologic examination of Aspergillus species. Am J Clin Pathol. 2013;139(1):55–61. https://doi.org/10.1309/AJCPO8VTSK3HRNUT.CrossRefPubMed

Fortún J, Martín-Dávila P, GomezGarcia de la Pedrosa E, Silva JT, Garcia-Rodríguez J, Benito D, et al. Galactomannan in bronchoalveolar lavage fluid for diagnosis of invasive aspergillosis in non-hematological patients. J Infect. 2016;72(6):738–44. https://doi.org/10.1016/j.jinf.2016.02.019.CrossRefPubMed

Shengli L, Ning H. A case of severe pulmonary aspergillosis. Chin J Mycol. 2020;15(3):170–2. https://doi.org/10.3969/j.issn.1673-3827.2020.03.011.CrossRef

10.

He B-C, Liu L-L, Chen B-L, Zhang F, Su X. The application of next-generation sequencing in diagnosing invasive pulmonary aspergillosis: three case reports. Am J Transl Res. 2019;11(4):2532–9.PubMedPubMedCentral

11.

Richardson M, Lass-Flörl C. Changing epidemiology of systemic fungal infections. Clin Microbiol Infect. 2008;14(Suppl):4. https://doi.org/10.1111/j.1469-0691.2008.01978.x.CrossRef

12.

Koehler P, Bassetti M, Kochanek M, Shimabukuro-Vornhagen A, Cornely OA. Intensive care management of influenza-associated pulmonary aspergillosis. Clin Microbiol Infect. 2019;25(12):1501–9. https://doi.org/10.1016/j.cmi.2019.04.031.CrossRefPubMed

13.

Ullmann AJ, Aguado JM, Arikan-Akdagli S, Denning DW, Groll AH, Lagrou K, et al. Diagnosis and management of Aspergillus diseases: executive summary of the 2017 ESCMID-ECMM-ERS guideline. Clin Microbiol Infect. 2018;24(Suppl 1):e1–38. https://doi.org/10.1016/j.cmi.2018.01.002.CrossRefPubMed

14.

Kosmidis C, Denning DW. The clinical spectrum of pulmonary aspergillosis. Thorax. 2015;70(3):270–7. https://doi.org/10.1136/thoraxjnl-2014-206291.CrossRefPubMed

15.

Kohno S, Izumikawa K, Ogawa K, Kurashima A, Okimoto N, Amitani R, et al. Intravenous micafungin versus voriconazole for chronic pulmonary aspergillosis: a multicenter trial in Japan. J Infect. 2010;61(5):410–8. https://doi.org/10.1016/j.jinf.2010.08.005.CrossRefPubMed

16.

Yoshida K, Kurashima A, Kamei K, Oritsu M, Ando T, Yamamoto T, et al. Efficacy and safety of short- and long-term treatment of itraconazole on chronic necrotizing pulmonary aspergillosis in multicenter study. J Infect Chemother. 2012;18(3):378–85. https://doi.org/10.1007/s10156-012-0414-7.CrossRefPubMed

17.

Vieira DF, Van Saene HK, Miranda DR. Invasive pulmonary aspergillosis after near-drowning. Intensive Care Med. 1984;10(4):203–4. https://doi.org/10.1007/bf00259439.CrossRefPubMed

18.

Hayes D Jr, Murphy BS, Lynch JE, Feola DJ. Aerosolized amphotericin for the treatment of allergic bronchopulmonary aspergillosis. Pediatr Pulmonol. 2010;45(11):1145–8. https://doi.org/10.1002/ppul.21300.CrossRefPubMed

19.

Chishimba L, Langridge P, Powell G, Niven RM, Denning DW. Efficacy and safety of nebulised amphotericin B (NAB) in severe asthma with fungal sensitisation (SAFS) and allergic bronchopulmonary aspergillosis (ABPA). J Asthma. 2015;52(3):289–95. https://doi.org/10.3109/02770903.2014.958853.CrossRefPubMed

20.

Godet C, Goudet V, Laurent F, Le Moal G, Gounant V, Frat JP, et al. Nebulised liposomal amphotericin B for Aspergillus lung diseases: case series and literature review. Mycoses. 2015;58(3):173–80. https://doi.org/10.1111/myc.12294.CrossRefPubMed

21.

Ram B, Aggarwal AN, Dhooria S, Sehgal IS, Garg M, Behera D, et al. A pilot randomized trial of nebulized amphotericin in patients with allergic bronchopulmonary aspergillosis. J Asthma. 2016;53(5):517–24. https://doi.org/10.3109/02770903.2015.1127935.CrossRefPubMed

22.

Leenders AC, de Marie S, ten Kate MT, Bakker-Woudenberg IA, Verbrugh HA. Liposomal amphotericin B (AmBisome) reduces dissemination of infection as compared with amphotericin B deoxycholate (Fungizone) in a rate model of pulmonary aspergillosis. J Antimicrob Chemother. 1996;38(2):215–25. https://doi.org/10.1093/jac/38.2.215.CrossRefPubMed

23.

Walsh TJ, Lewis RE, Adler-Moore J. Pharmacology of liposomal amphotericin B: an introduction to preclinical and clinical advances for treatment of life-threatening invasive fungal infections. Clin Infect Dis. 2019;68(Suppl 4):S241–3. https://doi.org/10.1093/cid/ciz091.CrossRefPubMedPubMedCentral

24.

Becker WK, Cioffi WG Jr, McManus AT, Kim SH, McManus WF, Mason AD, et al. Fungal burn wound infection. A 10-year experience. Arch Surg. 1991;126(1):44–8. https://doi.org/10.1001/archsurg.1991.01410250048008.CrossRefPubMed

25.

Sherif R, Segal BH. Pulmonary aspergillosis: clinical presentation, diagnostic tests, management and complications. Curr Opin Pulm Med. 2010;16(3):242–50. https://doi.org/10.1097/MCP.0b013e328337d6de.CrossRefPubMedPubMedCentral

26.

Franquet T, Müller NL, Giménez A, Guembe P, de La Torre J, Bagué S. Spectrum of pulmonary aspergillosis: histologic, clinical, and radiologic findings. Radiographics. 2001;21(4):825–37.CrossRefPubMed

27.

Ohba H, Miwa S, Shirai M, Kanai M, Eifuku T, Suda T, et al. Clinical characteristics and prognosis of chronic pulmonary aspergillosis. Respir Med. 2012;106(5):724–9. https://doi.org/10.1016/j.rmed.2012.01.014.CrossRefPubMed

Title: Invasive Aspergillus outbreak in inhalation injury: a case presentation and literature review
Authors: Shengli Liu
Zonghang Li
Jiansheng Zheng
Ning He
Publication date: 01-12-2022
Publisher: BioMed Central
Keywords: Bronchoscopy
Aspergillosis
Published in: BMC Infectious Diseases / Issue 1/2022
Electronic ISSN: 1471-2334
DOI: https://doi.org/10.1186/s12879-022-07366-7

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Invasive Aspergillus outbreak in inhalation injury: a case presentation and literature review

Abstract

Background

Case presentation

Conclusions

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Background

Case presentation

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2022

Evolution and spread of a highly drug resistant strain of Mycobacterium tuberculosis in Papua New Guinea

Presymptomatic, asymptomatic and post-symptomatic transmission of SARS-CoV-2: joint British Infection Association (BIA), Healthcare Infection Society (HIS), Infection Prevention Society (IPS) and Royal College of Pathologists (RCPath) guidance

Epidemiology and outcomes associated with carbapenem-resistant Acinetobacter baumannii and carbapenem-resistant Pseudomonas aeruginosa: a retrospective cohort study

Direct comparison of Xpert Xpress, FilmArray Respiratory Panel, Lumipulse antigen test, and RT-qPCR in 165 nasopharyngeal swabs

Spatiotemporally comparative analysis of three common infectious diseases in China during 2013–2015

Kinetics of humoral immune response over 17 months of COVID-19 pandemic in a large cohort of healthcare workers in Spain: the ProHEpiC-19 study

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page